[Pharm-policy] NaPro BioTherapeutics Overturns Bristol-Myers Squibb European Paclitaxel Administration Patent

[love@cptech.org]

http://www.stockhouse.com/news/news.asp?tick=NPRO&newsid=835070

 NaPro BioTherapeutics Inc Quick Quote: NPRO 10.62 (+0.02)  
NaPro BioTherapeutics Overturns Bristol-Myers Squibb European Paclitaxel
Administration Patent 
7/12/01 
 
>     Business Editors/Medical Writers

    BOULDER, Colo.--(BW HealthWire)--July 12, 2001--NaPro
BioTherapeutics, Inc. (Nasdaq:NPRO) announced today that it was
successful in opposing European Patent number 0 584 001, issued to
Bristol-Myers Squibb Corp. (NYSE:BMY) relating to methods of
administering paclitaxel, the active ingredient in Bristol-Myers
Squibb's anticancer drug, TAXOL(R), in Europe. The European Patent
Office ruled that this patent is now invalid. A related United Kingdom
administration patent opposed by NaPro last year was similarly revoked
by the United Kingdom courts.
    NaPro BioTherapeutics, Inc., headquartered in Boulder, Colorado, is
a biopharmaceutical company focused on the development, production and
licensing of complex natural-product pharmaceuticals as well as the
development and licensing of novel genetic technologies for applications
in agribiotechnology, pharmacogenomic, and human therapeutic and
diagnostic applications.


 
    
 
    CONTACT: NaPro BioTherapeutics, Inc. 
             Leonard Shaykin, 212/319-2800 (Chairman and CEO) 
             Gordon Link, 303/530-3891 (VP and CFO) 
                or 
             Burns McClellan, Inc. 
             Stephanie Diaz, 415/352-6262 (Investors) 
             sdiaz@sf.burnsmc.com